Latest news with #LeonidTimashev
Business Insider
10-07-2025
- Business
- Business Insider
ADC Therapeutics (ADCT) Receives a Buy from RBC Capital
RBC Capital analyst Leonid Timashev maintained a Buy rating on ADC Therapeutics on July 7 and set a price target of $5.00. The company's shares closed yesterday at $3.15. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Timashev is a 3-star analyst with an average return of 1.5% and a 43.80% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Legend Biotech, Biohaven Ltd., and Alkermes. Currently, the analyst consensus on ADC Therapeutics is a Moderate Buy with an average price target of $6.00. Based on ADC Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $17.4 million and a GAAP net loss of $38.6 million. In comparison, last year the company earned a revenue of $18.05 million and had a GAAP net loss of $46.61 million
Business Insider
10-07-2025
- Business
- Business Insider
RBC Capital Reaffirms Their Buy Rating on Nuvation Bio (NUVB)
In a report released on July 7, Leonid Timashev from RBC Capital maintained a Buy rating on Nuvation Bio, with a price target of $6.00. The company's shares closed yesterday at $2.37. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Timashev covers the Healthcare sector, focusing on stocks such as Legend Biotech, Biohaven Ltd., and Alkermes. According to TipRanks, Timashev has an average return of 1.5% and a 43.80% success rate on recommended stocks. Currently, the analyst consensus on Nuvation Bio is a Strong Buy with an average price target of $7.40, representing a 212.24% upside. In a report released on June 25, Citizens JMP also reiterated a Buy rating on the stock with a $6.00 price target. The company has a one-year high of $3.97 and a one-year low of $1.54. Currently, Nuvation Bio has an average volume of 5.58M. Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NUVB in relation to earlier this year. Last month, Kerry Wentworth, the CHIEF REGULATORY OFFICER of NUVB bought 50,000.00 shares for a total of $89,740.00.
Business Insider
10-07-2025
- Business
- Business Insider
RBC Capital Remains a Hold on Alkermes (ALKS)
RBC Capital analyst Leonid Timashev maintained a Hold rating on Alkermes on July 7 and set a price target of $40.00. The company's shares closed yesterday at $29.98. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Timashev covers the Healthcare sector, focusing on stocks such as Legend Biotech, Biohaven Ltd., and Alkermes. According to TipRanks, Timashev has an average return of 1.5% and a 43.80% success rate on recommended stocks. Currently, the analyst consensus on Alkermes is a Moderate Buy with an average price target of $40.00.
Yahoo
26-06-2025
- Business
- Yahoo
RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating
Nuvation Bio Inc. (NYSE:NUVB) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. RBC Capital analyst Leonid Timashev maintained a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) on June 17, lowering the price target to $6.00 from $10.00. The analyst told investors in a research note that the firm updated its model after the company's transformation into a commercial stage biotech and the recent approval of Ibtrozi to treat cancer. A close-up of researchers, carefully studying a biopharmaceutical compound in a laboratory. Timashev acknowledged that the firm sees some potential challenges for the launch of Ibtrozi, including near-term competitive headwinds and patient finding. However, RBC is optimistic that these headwinds will be outweighed by the drug's long treatment duration, favorable profile, and improving dx rates, supporting the positive rating for Nuvation Bio Inc. (NYSE:NUVB). The analyst also reasoned that the stock is steeply discounting the recently realized commercial opportunity. Nuvation Bio (NYSE:NUVB) is a biopharmaceutical company that develops therapeutic and differentiated candidates to tackle the gaps in oncology. It is advancing several clinical-stage candidates, including a bromodomain and extra-terminal (BET) inhibitor, a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, and a drug-drug conjugate (DDC). While we acknowledge the potential of NUVB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
24-06-2025
- Business
- Yahoo
RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating
Nuvation Bio Inc. (NYSE:NUVB) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. RBC Capital analyst Leonid Timashev maintained a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) on June 17, lowering the price target to $6.00 from $10.00. The analyst told investors in a research note that the firm updated its model after the company's transformation into a commercial stage biotech and the recent approval of Ibtrozi to treat cancer. A close-up of researchers, carefully studying a biopharmaceutical compound in a laboratory. Timashev acknowledged that the firm sees some potential challenges for the launch of Ibtrozi, including near-term competitive headwinds and patient finding. However, RBC is optimistic that these headwinds will be outweighed by the drug's long treatment duration, favorable profile, and improving dx rates, supporting the positive rating for Nuvation Bio Inc. (NYSE:NUVB). The analyst also reasoned that the stock is steeply discounting the recently realized commercial opportunity. Nuvation Bio (NYSE:NUVB) is a biopharmaceutical company that develops therapeutic and differentiated candidates to tackle the gaps in oncology. It is advancing several clinical-stage candidates, including a bromodomain and extra-terminal (BET) inhibitor, a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, and a drug-drug conjugate (DDC). While we acknowledge the potential of NUVB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
